Denosumab
Denosumab
About this item
Full title
Denosumab
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Drug discovery, 2010-08, Vol.9 (8), p.591-592
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the European Commission for the treatment of postmenopausal women with osteoporosis who are at increased risk of fracture, and for the treatment of bone loss associated with hormone ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after,...
Alternative Titles
Full title
Denosumab
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_754537468
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_754537468
Other Identifiers
ISSN
1474-1776
E-ISSN
1474-1784
DOI
10.1038/nrd3244
